Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose In some unusual cases, in patients with cervical cancer, an elevation of squamous cell carcinoma antigen (SCC-Ag) was not observed at diagnosis but was observed on recurrence, or vice versa. The objective of this study was to identify patient-, disease-,and treatment-related factors associated with this unusual level of SCC-Ag, and to determine whether SCC-Ag is a useful tumor marker in such patients. Materials and Methods Among 129 patients with recurrence, 14 who showed a normal SCC-Ag level at diagnosis but an elevated level at recurrence were classified as group I; 22 patients with an elevated SCC-Ag level at diagnosis but not at recurrence were classified as group II; and 76 patients with an elevated SCC-Ag level at both diagnosis and recurrence were classified as group III. Results In univariate analysis, unusual SCC-Ag showed statistically significant relationships with pathology and biochemical response to treatment. However, in the multivariate analysis, none of the clinicopathologic factors showed a statistical relationship with unusual levels of SCC-Ag. The 5-year disease-free survival rates for groups I, II, and III were 7.1%, 9.1%, and 0% (p=0.418), and the 5-year overall survival rates were 34.3%, 58.4%, and 33.3% (p=0.142), respectively. Conclusion The value of SCC-Ag has been confirmed in all patients; thus, check of SCC-Ag level at follow-up should be considered. Although no statistically significant differences were observed among the groups, we conclude that patients with a high initial SCC-Ag and elevated SCC-Ag at relapse have poor prognosis due to high SCC-Ag level.
Abstract
Purpose In some unusual cases, in patients with cervical cancer, an elevation of squamous cell carcinoma antigen (SCC-Ag) was not observed at diagnosis but was observed on recurrence, or vice versa. The objective of this study was to identify patient-, disease-,and treatment-related factors associated with this unusual level of SCC-Ag, and to determine whether SCC-Ag is a useful tumor marker in such patients. Materials and Methods Among 129 patients with recurrence, 14 who showed a normal SCC-Ag level at diagnosis but an elevated level at recurrence were classified as group I; 22 patients with an elevated SCC-Ag level at diagnosis but not at recurrence were classified as group II; and 76 patients with an elevated SCC-Ag level at both diagnosis and recurrence were classified as group III. Results In univariate analysis, unusual SCC-Ag showed statistically significant relationships with pathology and biochemical response to treatment. However, in the multivariate analysis, none of the clinicopathologic factors showed a statistical relationship with unusual levels of SCC-Ag. The 5-year disease-free survival rates for groups I, II, and III were 7.1%, 9.1%, and 0% (p=0.418), and the 5-year overall survival rates were 34.3%, 58.4%, and 33.3% (p=0.142), respectively. Conclusion The value of SCC-Ag has been confirmed in all patients; thus, check of SCC-Ag level at follow-up should be considered. Although no statistically significant differences were observed among the groups, we conclude that patients with a high initial SCC-Ag and elevated SCC-Ag at relapse have poor prognosis due to high SCC-Ag level.
참고문헌 (21)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Ferrandina G, "Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures", Gynecol Oncol, 107(1 Suppl 1), pp.S127~S132 (2007)
- Classe JM, "Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)", Gynecol Oncol, 102, pp.523~529 (2006)
- Lai CH, "Management of recurrent cervical cancer", Chang Gung Med J, 27, pp.711~717 (2004)
- Chou HH, "Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma", Int J Radiat Oncol Biol Phys, 51, pp.442~448 (2001)
- Bodurka-Bevers D, "Posttherapy surveillance of women with cervical cancer: an outcomes analysis", Gynecol Oncol, 78, pp.187~193 (2000)
- Strauss HG, "SCC antigen in the serum as an independent prognostic factor in operable squamous cell carcinoma of the cervix", Eur J Cancer, 38, pp.1987~1991 (2002)
- Bolli JA, "Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix", Gynecol Oncol, 55, pp.169~173 (1994)
- Bolger BS, "Prognostic value of preoperative squamous cell carcinoma antigen level in patients surgically treated for cervical carcinoma", Gynecol Oncol, 65, pp.309~313 (1997)
- Scambia G, "Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer", J Clin Oncol, 12, pp.2309~2316 (1994)
- Micke O, "The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cance", Anticancer Res, 20, pp.5113~5115 (2000)
- Esajas MD, "Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cance", J Clin Oncol, 19, pp.3960~3966 (2001)
- Chan YM, "Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective", Gynecol Oncol, 84, pp.7~11 (2002)
- Pras E, "Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment", Int J Radiat Oncol Biol Phys, 52, pp.23~32 (2002)
- Micke O, "The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy", Anticancer Res, 25, pp.1663~1666 (2005)
- Rose PG, "Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence", Am J Obstet Gynecol, 168(3 Pt 1), pp.942~946 (1993)
- Choi DH, "A study of relationship between the level of serum SCC antigen and recurrence patterns after treatment of uterine cervix cancer", J Korean Soc Ther Radiol Oncol, 17, pp.120~128 (1999)
- Yoon SM, "Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy", Radiat Oncol, 5, pp.78~ (2010)
- Gadducci A, "The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature", Crit Rev Oncol Hematol, 66, pp.10~20 (2008)
- Forni F, "Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness", Int J Radiat Oncol Biol Phys, 69, pp.1145~1149 (2007)
- 정배권, "The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix", Radiation oncology journal, 29(3), pp.191~198 (2011), 대한방사선종양학회